Biological Background of Kaiso (ZBTB33)

Kaiso, encoded by the ZBTB33 gene, is a member of the BTB/POZ zinc finger (BTB-ZF) protein family. It functions as a transcriptional repressor with a dual-specificity DNA-binding capacity: it can recognize methylated CpG dinucleotides (mCpG) in a sequence-independent manner, and it can also bind an unmodified consensus sequence known as the Kaiso-binding element (KBE; CTGCNA). This dual-binding mode distinguishes Kaiso from classical methyl-CpG-binding domain (MBD) proteins and positions it at the intersection of epigenetic silencing and sequence-specific transcriptional repression.

Kaiso interacts with p120-catenin (p120ctn), a component of the cadherin-catenin adhesion complex, and this interaction has been linked to nuclear signaling downstream of the Wnt pathway. Through sequestration of p120ctn, Kaiso's repressive activity on target genes such as MMP7, Wnt11, and siamois can be modulated. These roles implicate Kaiso in developmental biology, cell adhesion, and cancer progression.

Protein Structure and Key Domains

Kaiso contains two principal functional modules. The N-terminal BTB/POZ (Broad-Complex, Tramtrack, and Bric-à-brac / Pox virus and Zinc finger) domain mediates protein-protein interactions and homodimerization, and is essential for transcriptional repression activity through recruitment of corepressor complexes including NCoR and SMRT. The C-terminal region harbors three Krüppel-type C2H2 zinc finger motifs that are responsible for sequence-specific and methylation-dependent DNA binding.

Zinc fingers 2 and 3 are sufficient for recognition of methylated CpG pairs, while all three zinc fingers contribute to KBE recognition. The modular architecture of Kaiso allows it to integrate multiple regulatory inputs—epigenetic DNA methylation status and sequence context—into a unified transcriptional repressor output. Understanding this domain structure is important when designing biochemical assays such as electrophoretic mobility shift assays (EMSAs) or chromatin immunoprecipitation (ChIP) experiments using recombinant Kaiso protein.

Experimental Applications and Protocols

Recombinant Human Kaiso Protein (rp366852) is suitable for a range of in vitro biochemical and cell biology applications:

• Electrophoretic Mobility Shift Assay (EMSA): Use purified recombinant Kaiso to evaluate binding affinity to methylated CpG probes or KBE oligonucleotides. Include appropriate competitor DNA and antibody supershift controls to confirm specificity.
• Surface Plasmon Resonance (SPR) / Bio-Layer Interferometry (BLI): Quantify kinetic parameters (k_on, k_off, K_D) for Kaiso interactions with methylated DNA substrates or p120-catenin protein partners.
• Pull-down and Co-immunoprecipitation (Co-IP): Recombinant Kaiso can serve as bait to identify novel interaction partners or validate known interactors such as p120ctn, NCoR, or HDAC complexes.
• In vitro Transcription Repression Assays: Use in cell-free transcription systems to assess repressor activity on reporter templates containing KBE or mCpG elements.
• Antibody Validation: Recombinant protein provides a positive control antigen for ELISA, Western blot, and immunofluorescence antibody validation workflows.

When designing experiments, ensure that buffer conditions are compatible with zinc coordination (avoid chelating agents such as EDTA at high concentrations that may disrupt zinc finger integrity). Include a no-protein negative control and a matched IgG control in all binding assays.

Handling, Storage, and Quality Considerations

To maintain full biological activity of Recombinant Human Kaiso Protein, adhere to the following handling guidelines:

• Aliquoting: Upon receipt, centrifuge briefly to consolidate the solution, then prepare single-use aliquots to minimize freeze-thaw cycles. Repeated freeze-thaw cycles can reduce protein activity and promote aggregation.
• Storage temperature: Follow the specific temperature recommendations on the product datasheet. Typically, recombinant proteins are stored at −80 °C for long-term preservation and at 4 °C for short-term use (≤1 week).
• Buffer compatibility: Confirm that the supplied formulation buffer is compatible with downstream assay conditions. If buffer exchange is required, use dialysis or desalting columns pre-equilibrated with your target buffer.
• Protein quantification: Determine working concentration by absorbance at 280 nm (A₂₈₀) using the calculated extinction coefficient, or by a colorimetric assay (BCA or Bradford) compatible with the buffer components.
• Quality verification: Confirm identity and purity by SDS-PAGE and, if required, by Western blot using a validated anti-Kaiso or anti-tag antibody prior to use in critical experiments.

Always consult the product-specific Certificate of Analysis (CoA) for lot-specific purity, activity, and endotoxin data.

Kaiso in Cancer and Disease Research

Kaiso has attracted significant attention in oncology research owing to its roles in regulating genes involved in cell proliferation, epithelial-to-mesenchymal transition (EMT), and Wnt signaling. Altered Kaiso expression or localization has been reported in several cancer types, including colorectal, breast, and lung cancers. In some tumor contexts, cytoplasmic sequestration of Kaiso by p120-catenin relieves transcriptional repression of pro-tumorigenic Wnt target genes, while nuclear Kaiso activity may suppress or activate distinct gene sets depending on promoter methylation context.

Recombinant Human Kaiso Protein enables researchers to dissect these mechanisms in controlled biochemical settings, independently of endogenous protein levels. It is particularly valuable for reconstitution experiments aimed at identifying the minimal protein components required for methylation-dependent gene silencing complexes, and for screening small-molecule inhibitors that disrupt Kaiso-DNA or Kaiso-p120ctn interactions as potential therapeutic strategies.

Note: Specific expression-level data and clinical correlations cited in the literature should be verified against primary sources. Researchers are encouraged to consult current peer-reviewed publications for the most up-to-date findings.